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Background: Haemodialysis results in a left ventricular hypertrophic response. It is unclear whether tight blood
pressure control or particular medications might attenuate this response. We sought to determine, in a pre-dialysis
cohort on atenolol, whether Losartan might attenuate left ventricular hypertrophy post arteriovenous fistula
creation in end stage kidney disease.
Materials and methods: Placebo controlled double blind randomisation of 26 patients to fixed dose atenolol plus
fixed dose losartan or placebo occurred 1 day prior to fistula creation. Pre-randomisation echocardiography was
repeated at 1 week and 1-month. Measurement was undertaken of blood pressure, heart rate, brain natriuretic
peptide, serum creatinine and estimated glomerular filtration rate. The primary pre-specified endpoint was the
change in left ventricular mass at 1 month. Non-parametric statistical comparison was performed within and
between groups.
Results: There was no difference in left ventricular mass between our groups 1-month post fistula creation. In the
entire cohort, change in left ventricular mass was driven by changes in blood pressure and volume loading. Blood
pressure changes correlated with left ventricular mass changes seen shortly post arteriovenous fistula creation,
suggesting blood pressure control during this time period may be an important part of the management of end
stage kidney disease.
Conclusions: We did not see an advantage with the use of losartan with respect to diminution of the LVM
response. However, our demonstrated change in LVM was relatively small compared to previous literature and
suggests a possible role for beta blockade as a neurohormonal modulator around the time of arteriovenous fistula
creation.
Trial registration: Clinical trials.gov (NCT00602004).
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Left ventricular hypertrophy is common in the end
stage kidney disease population [1] prior to dialysis
commencement, where it appears to relate to both
hypertension and anemia [2]. Creation of an arterioven-
ous fistula (AVF) for long-term renal replacement ther-
apy further increases left ventricular wall thickness
causing left ventricular hypertrophy (LVH)[3,4] and
increased mass (LVM) and cardiac chamber enlarge-
ment [5,6]. Occasionally, a more extreme response
occurs with the development of high output cardiac
failure following creation of an AVF [7]. Reversibility of
these changes in cardiac parameters has been documen-
ted post renal transplant in patients in whom functional
AVF are closed [3,8,9].
Both systolic heart failure and end stage kidney disease
(ESKD) have a heightened sympathetic nervous system
(SNS) response [10,11] .In heart failure there is evidence
of mortality benefit with ACE inhibitors and beta-blockers
[12,13]. It is unknown whether these medications might
attenuate the cardiac response to AVF creation.
A small number of studies have suggested that losar-
tan, an angiotensin receptor blocker (ARB), might di-
minish the LVH response to volume overload. This has
been seen in a rat model of volume overload with induc-
tion of aortic regurgitation [14], and in humans on
established haemodialysis (HD) [15,16], although one of
these papers also differed with respect to BP variability
between the losartan and the control group [15]. It is
accepted that effective treatment of hypertension
achieves a decrease in LVM in the wider population [17]
and in patients on HD [18], although whether an incre-
mental drug class specific effect on LVH may exist once
BP is well controlled is less clear.
A mild state of volume overload has been seen to
occur early post AVF creation [19], with changes in both
cardiac function and increases in atrial natriuretic pep-
tide (ANP) levels despite a lack of change in left atrial
(LA) size. Current echocardiography guidelines recom-
mend measurement of LA volume (LAV), not size, as a
better marker of atrial remodelling with a more signifi-
cant relationship to cardiovascular disease [20]. Concur-
rently, a move to measurement of brain natriuretic
peptide (BNP) instead of ANP has occurred in the arena
of heart failure research and management [21].
BNP, a more stable measure in renal disease than NT-
proBNP [22], correlates with left ventricular mass index
(LVMI) in end stage kidney disease (ESKD) patients and
is known to increase with volume expansion and cardio-
myocyte stretch [22,23]. BNP has been shown to predict
mortality in HD patients without heart failure [23], and
both ventricular arrhythmias and mortality in a meta-
analysis of patients with reduced ventricular ejection
fraction (EF) [21].We sought to determine, in a prospective double blind
randomised trial, whether the addition of losartan to ate-
nolol in a population undergoing AVF creation attenu-
ated the increase in LVM. All patients were commenced
on atenolol in order to minimise, as much as possible,
differences either in type of antihypertensive medications
or blood pressure control achieved between the losartan
and placebo groups.
Additionally, we assessed BNP level and changes in




Recruitment proved to be difficult, with numbers of
patients being considered for an elective AVF creation as
they approached clinical need for dialysis being insuffi-
cient to achieve the sample size envisaged. Recruitment
was thus terminated after a 2-year period, during which
a total of 26 patients were recruited. This sample size
gave us 67% power to detect a difference between the
losartan and the placebo group. All 26 patients had a
baseline echocardiogram, 21 underwent a week 1 study
and 20 underwent a week 4 study (Figure 1).
Treatment phase
Randomisation resulted in 14 patients in the atenolol
plus placebo and 12 patients in the atenolol plus losartan
arm. The investigators were blinded with respect to
which patients were taking either placebo or losartan.
Baseline characteristics in the groups are shown in
Table 1. The Losartan group was statistically significantly
older (2p = 0.019), with no significant differences seen
between the groups in sitting SBP, DBP or heart rate, or
in body weight or body surface area (BSA). Median BNP
levels were higher with a greater IQR in the losartan
group, but this was not statistically significant.
Baseline echocardiography
At baseline, echocardiography results between the pla-
cebo and losartan groups showed no significant differ-
ence between the randomised groups with respect to
median LVM, RWT, CO, E/E’, LAV or EF (Table 2).
Echocardiography at 1 week
The only statistically significant result between the
groups at 1 week was in E/E’ which was greater in the
losartan group (p = 0.04). There was no difference be-
tween the groups in BP, HR, BNP, LVM, LVMI, RWT,
CO, LAV or EF (data not presented further). In both the
losartan and placebo group however, CO and CI were
statistically greater by 1 week compared with baseline
(losartan: CO P= 0.015, CI P = 0.025; placebo: CO
P= 0.026, CI P = 0.016). Both CO and CI had trended
Figure 1 Flowchart of study methodology and participation at each time point.
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no statistically significant difference seen on comparison
with either the baseline or 1 week result.Echocardiography at 1 month
At 1 month, there were no significant differences seen
between the placebo and losartan groups in blood pres-
sure, heart rate, BNP, LVM, CO, LAV, EF.
Compared with baseline, at 1 month the losartan
group had lower sitting SBP (2p = 0.042) and a higher
LVM (2p = 0.028).(Table 3) However, there was no
change in LVMI and this is presumably due to the
change in weight between these time points although
this did not reach statistical significance [median 74.2
(71.4–88.3) kg vs median 80.8 (74–90.4), 2p = 0.07]. The
losartan group also had a statistically significant decrease
in hemoglobin during this time, from 111.5 (104–128.5)
to 106 (101.5–117.0) (2p = 0.013). This may have affected
the absolute LVM increase, as a strong negative correl-
ation was present at baseline between hemoglobin and
LVM (r =−0.7, 2p = 0.018). At 1 month, the correlation
between hemoglobin and LVM was no longer statisti-
cally significant, possibly because of lower numbers of
results being available. The possibility of volume over-
load/overhydration exists to explain this acute change in
weight and haemoglobin. Of interest however, the BP
decrease during this period (median −17/- 4 mmHg)
appears to suggest that significant volume overload was
unlikely.In contrast, at 1 month there were no differences in
clinical or biochemical data compared with baseline in the
placebo group. In the echocardiographic data, the only dif-
ference in the placebo group was E/E’, which decreased
from 11.4 (9.8–14) to 10.4 (8.8–13.2) (2p = 0.036). No
significant change in hemoglobin or weight was seen.The hemodynamic effects of creating an AVF
In view of both the smaller sample size than anticipated
and the fact that BP did not differ between the groups at
the time points of interest, we decided to investigate the
hemodynamic changes documented in the entire cohort,
regardless of whether they had received losartan or pla-
cebo. All subjects in this study had a clinically patent
AVF on the day of each echocardiogram.Percentage changes in hemodynamics and BNP
When considered as one group (Losartan and placebo
combined) the cohort showed significant early
hemodynamic changes in response to the creation of an
AVF. By 1 week, compared with baseline, EF, CO and
LAV had risen a median of 8% (p =0.05), 24% (p = 0.001)
and 19% (p = 0.031) respectively. Sitting SBP decreased
5% (ns) and LVMI decreased by 1.5% (ns). The biochem-
ical endpoints were not significantly different.
In contrast, the 1-month results, compared to the 1-
week data, demonstrated no further statistically signifi-
cant changes. It is possible that the smaller subject num-
bers for comparison between 1 week and 1 month
Table 1 Baseline characteristics at randomisation
Variable Losartan (n= 12) Placebo (n = 14)
Age (y) 66.5 (56–73) 57.5 (38.5–63)a
Gender (F: M) 4: 8 6: 8
eGFR 9.5 (6–16) 12 (10–14.5)
Hemoglobin 111.5 (104–128.5) 117 (111–138)
Creatinine 465 (322.5–597.3) 440 (339–480)
sSBP (mmHg) 1142 (132–160) 137 (130–153.5)
sDBP (mmHg) 74 (72–80) 78 (70–86)
sHR (bpm) 64 (60–74) 68 (61–74)
Weight (kg) 74.2 (71.4–88.3) 80 (70–89.4)
BSA (kg/m2) 1.90 (1.76–2.10) 1.91 (1.79–2.06)
BNP (ng/L) 285 (65–1194) 163 (63–303.3)
Additional antihypertensive
medications (n) (non protocol)
2.0 (0.5–2.5) 2.0 (0–3)
This table shows the gender spread, age, estimated glomerular filtration rate
(eGFR), sitting (s) systolic (SBP), diastolic blood pressure (DBP) and heart rate
(HR), weight and body surface area (BSA), brain natriuretic peptide (BNP)
measurement and the additional number of antihypertensive medications
(excluding protocol medications) in the atenolol plus losartan (losartan) and
atenolol plus placebo (placebo) groups. Data is expressed as median
(interquartile range) other than for gender, which is expressed as a ratio.
Statistical comparison was undertaken by the Mann–Whitney U test.
Comparison of the gender spread was undertaken with a Chi square test.
Statistically significant differences are marked by the letter a (a). (Please note:
non protocol medications with an antihypertensive effect included: calcium
channel blockers, diuretics, prazosin, glyceryl trinitrate patch and moxonidine).
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Correlations
Baseline LVM and haemoglobin were significantly nega-
tively correlated (r =− 0.5, 2P = 0.008) for LVM and
(r =−0.4, 2P = 0.032) for LVMI.Table 2 Results at baseline and 1 month in both the Losartan
Variable Losartan (A) baseline Losartan (B) 1 month
sSBP (mmHg) 142 (132–160) 129 (117–149)a
sDBP (mmHg) 74 (72–80) 70 (64–84)
sHR (bpm) 64 (60–74) 62 (56–80)
BNP 285 (65–1194) 325 (206–1798.5)
LVM (gm) 199.1 (148.5–225.2) 218.4 (146.5–262.2)a
LVMI (gm/m2) 99.6 (72.8–114.3) 83.5 (69.8–112)
RWT 0.40 (0.32–0.45) 0.36 (0.32–0.41)
CO (L/min) 5.3 (4.5–5.6) 5.9 (4.5–7.3)
E/E’ 15.0 (10.0–21.0) 12 (8.8–17.3)
LAV (mLs) 66.5 (54.8–75.6) 74.3 (59.8–80.5)
EF (%) 55 (47–57.8) 52.5 (49.3–56.8)
This table shows the sitting systolic (SBP) and diastolic (DBP) blood pressure and he
LVM index (LVMI), relative wall thickness (RWT), cardiac output (CO), E/E’, left atrial v
and atenolol plus placebo (placebo) groups at baseline (A) and 1 month (B). Data w
U) in the column labelled P (next to A for comparisons at baseline and next to B fo
1 month) when statistical significance was denoted by the letter a (a) if P <0.05 comLinear regression
Univariate linear regression demonstrated that the statis-
tically significant variables with 1 month LVM were
baseline LVM (p< 0.001), baseline hemoglobin
(2p = 0.003) and baseline BNP (2p = 0.025). Neither SBP
nor medication arm was statistically significant. Multi-
variate linear regression with these variables resulted in
only baseline BNP (2p< 0.001) and baseline LVM
(2p< 0.001) remaining statistically significant.
Multivariate analysis of the prercentage change in
LVM (change in LVM/original LVM) during treatment
demonstrated that the percentage change in sitting SBP
(2p = 0.003) and in BNP (2p = 0.016) were both
significant.
Discussion
To our knowledge, this is the first study of prophylactic
neurohormonal modulation in the early setting of AVF
creation. The timing of our data collection (1 week and
1 month post AVF creation) was predicated on the stud-
ies of Iwashima [7] and Ori [19], both of which docu-
mented changes in CO and LV size within a fortnight of
AVF creation. They did not calculate LVM but reported
a statistically significant increase in end diastolic dimen-
sion without a significant change in wall thickness. Al-
though we doubled the follow-up time compared to
these studies, and recruited more participants than ei-
ther, it is possible that the early endpoint at 1 month
precluded documentation of the maximum change in
LVM. Recently published data however supports the
timing of our study with respect to haemodynamic mea-
sures: 21 subjects studied at 2 weeks and 3 months post
AVF creation showed little subsequent alteration in
blood pressure or CO beyond the first assessmentand Placebo groups
Placebo (A) baseline Placebo (B) 1 month P
137 (130–153.5) 138 (127–141.5) A ns B ns
78 (70–86) 79 (70–85.5) A ns B ns
68 (61–74) 72 (66–78) A ns B ns
163 (63–303.3) 214 (144–277.5) A ns B ns
182.7 (143.5–205.0) 173.8 (151.1–204.9) A ns B ns
91.3 (77.6–106.8) 92.7 (78.4–107.5) A ns B ns
0.40 (0.34–0.47) 0.37 (0.35–0.42) A ns B ns
4.4 (3.7–5.9) 5.3 (4.6–6.9) A ns B ns
11.4 (9.8–14.0) 10.4 (8.8–13.2)a A ns B ns
65.0 (50.1–82.2) 65.1 (59.4–81.3) A ns B ns
52.5 (47.8–58.8) 52 (51–60) A ns B ns
art rate (HR), brain natriuretic peptide (BNP), left ventricular mass (LVM) and
olume (LAV) and ejection fraction (EF) in the atenolol plus losartan (losartan)
as compared utilising non-parametric tests: between groups (Mann–Whitney
r comparisons at 1 month) and within groups (Wilcoxon), (from baseline to
pared to baseline. (P denotes a two-tailed p value).
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formation on LVM,which was our major endpoint.
Increased LVM is an important risk factor for cardio-
vascular morbidity and mortality, both in the wider
population [25] and HD patients.[26] In the general
population, treatment of hypertension decreases LVH
and LVM [27] as well as the clinical end points of car-
diovascular morbidity and mortality [28].
We did not find that losartan attenuated the LVM re-
sponse to AVF creation, with 67% power in terms of
numbers recruited suggesting that the negative finding is
likely to be a true finding. All our patients were treated
to the same BP goals, with addition or up-titration of
antihypertensive agents as required. This allowed us to
also look at the entire cohort with respect to the acute
and short-term cardiac effects of AVF creation. In doing
so, the importance of BP on LVM is evident. Within a
month of AVF creation, our cohort showed a change in
LVM in response to changes in systolic blood pressure
and volume loading (as evidenced by the relationship
with BNP). This is an important finding, as the role of
BP control in ESRD is debated, particularly with respect
to whether the same threshold for and goals of treat-
ment should apply as in the wider population [29]. Data
in the non-ESRD population suggests benefits beyond
BP lowering with some antihypertensive agents, particu-
larly renin-angiotensin system antagonists [30]. There is
little data on the response to different antihypertensive
medications in the ESRD population.
Some significant differences also exist between our
study and the published literature addressing the use of
ARBs. The study from which we determined our power
calculation had a very significant diminution in LVM
over a 6-month period in 10 patients on losartan [16].
Notably, a greater change was also seen in hemoglobin
(average difference of 2.2 g/dL compared with 1.8 g/dL
in the ACEI and 0.7 g/dL in the calcium channel blocker
arm). No treatment target for BP was identified, though
the article states that no differences existed between the
groups. From the information provided it appears that
none of these patients were prescribed a BBl. Two other
studies have a greater number of patients and longer fol-
low up, but were also performed after commencement
of HD, not during fistula creation. Mitsuhashi [15]
recruited 40 patients on established HD, of whom half
were treated with losartan. A positive effect was seen on
LVM after 6 and 12 months, evident despite an appar-
ently matched decrease in BP between the losartan and
control groups. Concomitant BBl was prescribed in a
small number of patients (2 in the control group and 3
in the losartan group). BP at recruitment was lower in
our study than in either of these losartan positive stud-
ies. One other study, of patients 2 months post com-
mencement of HD, was similar in size to ours (24patients in total, divided into 2 arms) of which one arm
received a high dose of losartan (100 mg) thrice weekly
[31]. They found regression in LVM over 12 months in
the losartan treated group vs placebo. There was a sig-
nificant decrease in SBP in this group compared with
pre treatment values that appears greater than the
change seen in the control group on the graphical repre-
sentation provided.
Data with respect to the use of beta-blockers in the
HD population, in the absence of systolic heart failure,
is limited [32]. Pathophysiologically, a rationale for their
prescription exists given the recognition that HD is a
state of chronic SNS activation [10,33,34]. The failure
to see a difference between the two groups in our study
may be because all patients were also on a beta-blocker,
decreasing the additional effect that could be ascribed
to short-term use of losartan. It is possible that the lack
of significant change in BNP during this study supports
a beneficial effect of beta-blockade, as this has previ-
ously been documented to increase significantly post
AVF creation [7]. A retrospective study of long-term
dialysis patients has previously shown a lower risk of
heart failure and death in patients who were on a beta-
blocker compared to those without [35]. A prospective
study of dialysis patients with systolic heart failure
showed an improvement in functional status and EF
with a diminution in LV volume over 12 months with
use of carvedilol [36].Limitations
This is a small study that did not recruit the necessary
numbers for a definitive conclusion as to whether losar-
tan diminishes the LVM response to AVF creation in
patients where BP was treated to target and in whom
beta-blockers were ubiquitously prescribed.Conclusions
Our aim was to determine whether pre-emptive use of
an ARB decreased the LVM response to AVF creation.
We were not able to demonstrate a difference between
our groups with respect to LVM change, but of interest
the difference in LVM in our entire cohort was not sig-
nificant over this period of time. Likewise, SBP did not
alter significantly. However, when the change in these
variables was considered as a percentage change from
baseline in the entire cohort, they were significantly cor-
related. We conclude that control of BP during the peri
AVF creation time may be of long-term benefit and sug-
gest that beta blockade may provide complementary
benefit in altering the cardiac remodelling effects of fis-
tula creation. Our study suggests that a future study with
prophylactic beta blocker use in ESRD prior to AVF cre-
ation may be warranted.
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Recruitment phase
All patients with ESKD (GFR= 15–30 mLs/min) at the
Royal Melbourne Hospital (a tertiary referral hospital)
being considered for elective AVF creation in prepar-
ation for haemodialysis were offered participation in the
study.
Inclusion and exclusion criteria
Patients had to be> 18 and< 85 years of age.
Pre-menopausal women had to be on contraception in
view of potential randomisation to losartan with its
known teratogenic effects [37]. Baseline echocardiog-
raphy was required to demonstrate normal EF (defined
as> 45%).
Active exclusion criteria were hyperkalaemia, recent
(within 6 months) myocardial infarction or stroke, un-
controlled hypertension (SBP> 160 mmHg or DBP
> 100 mmHg), atrial fibrillation, greater than mild aortic
stenosis or greater than moderate mitral regurgitation
and any patient factor that would interfere with protocol
compliance.
Screening and randomisation phase
After screening for suitability, a 2-week wash out period
was undertaken for all patients on angiotensin converting
enzyme inhibitor (ACEI), angiotensin receptor blocker
(ARB) or beta-blocker (BBl). Other antihypertensive
agents were introduced if clinically required during this
time. Patients were randomised after 4 weeks of adequate
BP control (SBP range of 130–150 mmHg, DBP range of
80–90 mmHg) into either atenolol (25 mg) and placebo
or atenolol (25 mg) and losartan (50 mg) arms in a 1: 1
ratio the day prior to AVF creation. Of the 26 patients,
25 had a native AVF (13 proximal, 12 distal) and 1 had a
graft. Haemodialysis was only commenced in 1 patient
during the study and this patient’s participation was ter-
minated at that time (Figure 1).
Treatment phase
Patients were clinically assessed at 1 and 4 weeks post
AVF creation by a brief history and examination, with
recording of sitting systolic (SBP) and diastolic (DBP)
blood pressures and heart rate (average of 3 measures
over 5 minutes). Blood was drawn for biochemical
assessment.
Echocardiography, with a pre specified protocol, was
performed at these time points on a Vivid 7 (GE Med-
ical) digital machine, by 1 of 3 cardiac technologists.
Studies were stored and subsequently reported by 1 of 2
cardiologists blinded both to patient identity and treat-
ment arm.
LVM was calculated as LVM (g) = 0.8[1.04(LVIDD+
IVST+PWT)3 – LVIDD3] +0.6 where LVIDD= leftventricular internal dimension in diastole, IVST= inter-
ventricular septal thickness and PWT=posterior wall
thickness [20]; biplane LV volume determination
allowed calculation of biplane Simpson’s EF; diastolic
function was determined by assessment of mitral valve
inflow (E and A wave velocity) and with pulse wave
tissue Doppler imaging (TDI) assessment of septal E’
and subsequent calculation of preload as E/E’. CO [38]
and LAV [20] were calculated and right atrial pressure
[11,20] and right ventricular systolic pressure (RVSP)
[38] were estimated according to established guidelines.
Determination of relative wall thickness (defined as
RWT= {2 × posterior wall thickness}/left ventricular in-
ternal diameter in diastole}) allowed categorisation into
concentric and eccentric hypertrophy according to
RWT ≥ 42 and RWT< 42 respectively [39].
End point
The pre specified primary endpoint was a between group
difference in the change in LVM from baseline to
1 month.
Ethics approval
The RMH Human Research and Ethics Committee
granted ethics approval (HREC 2006.059) and all partici-
pants gave informed consent. The study adhered to the
principles of the Declaration of Helsinki. Janssen Cilag
provided funding for losartan and matching placebo
tablets. The company had no input into the research de-
sign or results analysis.
Statistics
Power calculation (90% at α= 0.05) determined sample
size to be 24 patients per arm based on a published find-
ing of a 15% LVM difference in a study comparing losar-
tan with both enalapril and amlodipine group [16].
Data is presented as median (interquartile range).
Non-parametric tests were undertaken for comparison
between and within groups. Percentage changes from
baseline to 1 week and from 1 week to 1 month are pre-
sented. Spearmans rho test was used for correlation.
Univariate and multivariate linear regression was under-
taken to explore the primary end point of LVM at
1 month. All statistics were explored using SPSS (PASW
18.0).
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